WO2002008716A3 - Procede de criblage de peptides utilisables en immunotherapie - Google Patents

Procede de criblage de peptides utilisables en immunotherapie Download PDF

Info

Publication number
WO2002008716A3
WO2002008716A3 PCT/FR2001/002387 FR0102387W WO0208716A3 WO 2002008716 A3 WO2002008716 A3 WO 2002008716A3 FR 0102387 W FR0102387 W FR 0102387W WO 0208716 A3 WO0208716 A3 WO 0208716A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
sequence
class
derived
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2001/002387
Other languages
English (en)
Other versions
WO2002008716A2 (fr
Inventor
Kostas Kosmatopoulos
Sophie Tourdot
Antonio Scardino
David Alexandre Gross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Gustave Roussy (IGR), Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut Gustave Roussy (IGR)
Priority to US10/333,430 priority Critical patent/US7425606B2/en
Priority to CA2416761A priority patent/CA2416761C/fr
Priority to EP01956629A priority patent/EP1309860B1/fr
Priority to AU2001278555A priority patent/AU2001278555A1/en
Priority to DK01956629T priority patent/DK1309860T3/da
Priority to DE60131413T priority patent/DE60131413T2/de
Publication of WO2002008716A2 publication Critical patent/WO2002008716A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002008716A3 publication Critical patent/WO2002008716A3/fr
Priority to US12/186,856 priority patent/US7976843B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)

Abstract

Procédé d'identification d'épitopes sous-dominants/cryptiques présentés par une molécule HLA de classe I ; ce procédé comprend au moins les étapes suivantes :a) le choix, à partir de la séquence d'une protéine vis-à-vis de laquelle on souhaite induire une réponse cytotoxique T, d'au moins une séquence peptidique de 8 à 11 acides aminés susceptible de constituer un épitope de ladite protéine présenté par une molécule HLA de classe I, et correspondant ô un peptide ô faible affinité pour ladite molécule HLA de classe I et non-immunogène ;b) la préparation, pour chaque séquence sélectionnée, d'un peptide variant dérivé de ladite séquence par substitution de l'acide aminé N-terminal par un résidu tyrosine ; c) la détermination de l'immunogénicité de chaque peptide variant obtenu à l'étape b) par la sélection, parmi ceux-ci, de chaque peptide immunogène, générant une réponse CTL spécifique vis-à-vis de cellules cibles exprimant la protéi ne dont il est issu et l'identification de la séquence peptidique dont dérive ledit peptide immunogène.Applications dudit procédé au criblage de peptides utilisables en immunothérapie.
PCT/FR2001/002387 2000-07-21 2001-07-20 Procede de criblage de peptides utilisables en immunotherapie Ceased WO2002008716A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US10/333,430 US7425606B2 (en) 2000-07-21 2001-07-20 Method for screening peptides for use in immunotherapy
CA2416761A CA2416761C (fr) 2000-07-21 2001-07-20 Procede de criblage de peptides utilisables en immunotherapie
EP01956629A EP1309860B1 (fr) 2000-07-21 2001-07-20 Procede de criblage de peptides utilisables en immunotherapie
AU2001278555A AU2001278555A1 (en) 2000-07-21 2001-07-20 Method for screening peptides for use in immunotherapy
DK01956629T DK1309860T3 (da) 2000-07-21 2001-07-20 Fremgangsmåde til screening af peptider til anvendelse i immunterapi
DE60131413T DE60131413T2 (de) 2000-07-21 2001-07-20 Verfahren zum auffinden von peptiden zur verwendung in der immuntherapie
US12/186,856 US7976843B2 (en) 2000-07-21 2008-08-06 Method for screening peptides for use in immunotherapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0009591A FR2812087B1 (fr) 2000-07-21 2000-07-21 Procede de criblage de peptides utilisables en immunotherapie
FR00/09591 2000-07-21

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10333430 A-371-Of-International 2001-07-20
US12/186,856 Division US7976843B2 (en) 2000-07-21 2008-08-06 Method for screening peptides for use in immunotherapy

Publications (2)

Publication Number Publication Date
WO2002008716A2 WO2002008716A2 (fr) 2002-01-31
WO2002008716A3 true WO2002008716A3 (fr) 2003-02-27

Family

ID=8852782

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/002387 Ceased WO2002008716A2 (fr) 2000-07-21 2001-07-20 Procede de criblage de peptides utilisables en immunotherapie

Country Status (11)

Country Link
US (2) US7425606B2 (fr)
EP (1) EP1309860B1 (fr)
AT (1) ATE378590T1 (fr)
AU (1) AU2001278555A1 (fr)
CA (1) CA2416761C (fr)
DE (1) DE60131413T2 (fr)
DK (1) DK1309860T3 (fr)
ES (1) ES2296778T3 (fr)
FR (1) FR2812087B1 (fr)
PT (1) PT1309860E (fr)
WO (1) WO2002008716A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
IL150961A0 (en) 2000-02-04 2003-02-12 Univ Duke Human immunodeficiency virus vaccine
WO2001060391A1 (fr) * 2000-02-15 2001-08-23 Regents Of The University Of California Vaccin universel et methode de traitement du cancer utilisant la transcriptase inverse de la telomerase
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
EP1752160A3 (fr) * 2001-04-06 2007-05-30 Mannkind Corporation Sequences d'epitopes
WO2003008537A2 (fr) * 2001-04-06 2003-01-30 Mannkind Corporation Sequences d'epitope
DE602006006046D1 (de) 2005-05-09 2009-05-14 Vaxon Biotech Verwendung nativer peptide und deren optimierter derivate zur impfung
WO2007073768A1 (fr) * 2005-12-23 2007-07-05 Vaxon Biotech Polypeptide immunogene compose de peptides cryptiques optimises derives d'antigenes tumoraux et ses utilisations
EP1887084A1 (fr) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmides avec l'action immunologique
WO2012023033A2 (fr) 2010-08-18 2012-02-23 Purdue Pharma L.P. Immunogènes peptidiques améliorés
RU2013157923A (ru) * 2011-05-26 2015-07-10 ДЖИНЕИУС БАЙОТЕКНОЛОДЖИ ИНВЕСТМЕНТС, ЭлЭлСи Терапия на основе модулирования иммунодоминантности
WO2021133742A1 (fr) * 2019-12-23 2021-07-01 The Regents Of The University Of California Stabilisation de complexes cmh
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004045A1 (fr) * 1989-09-20 1991-04-04 Board Of Regents, The University Of Texas System Prophylaxie et therapie du syndrome d'immunodeficience acquise
WO1995027901A1 (fr) * 1994-04-11 1995-10-19 Ixsys, Inc. Motifs de liaison a des peptides de classe i
WO1997035193A1 (fr) * 1996-03-21 1997-09-25 Imperial College Of Science, Technology And Medicine Peptides cryptiques et leur procede d'identification
WO2000002581A1 (fr) * 1998-07-08 2000-01-20 Norsk Hydro Asa Peptides antigenes derivees de la telomerase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3908271B2 (ja) * 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
CA2344972A1 (fr) * 1998-10-29 2000-05-11 Dana-Farber Cancer Institute, Inc. Immunotherapie et diagnostic du cancer au moyen d'antigenes universels associes a des tumeurs tels que htert
WO2001060391A1 (fr) * 2000-02-15 2001-08-23 Regents Of The University Of California Vaccin universel et methode de traitement du cancer utilisant la transcriptase inverse de la telomerase
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004045A1 (fr) * 1989-09-20 1991-04-04 Board Of Regents, The University Of Texas System Prophylaxie et therapie du syndrome d'immunodeficience acquise
WO1995027901A1 (fr) * 1994-04-11 1995-10-19 Ixsys, Inc. Motifs de liaison a des peptides de classe i
WO1997035193A1 (fr) * 1996-03-21 1997-09-25 Imperial College Of Science, Technology And Medicine Peptides cryptiques et leur procede d'identification
WO2000002581A1 (fr) * 1998-07-08 2000-01-20 Norsk Hydro Asa Peptides antigenes derivees de la telomerase

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, HUDRISIER DENIS ET AL: "Relative implication of peptide residues in binding to major histocompatibility complex class I, H-2D-b: Application to the design of high-affinity, allele-specific peptides.", XP002170619, Database accession no. PREV199598517001 *
MOLECULAR IMMUNOLOGY, vol. 32, no. 12, 1995, pages 895 - 907, ISSN: 0161-5890 *
OUKKA M, MANUGUERRA JC, LIVADITIS N, TOURDOT S, RICHE N, VERGNON I, CORDOPATIS P, KOSMATOPOULOS K.: "Protection against lethal viral infection by vaccination with nonimmunodominant peptides", JOURNAL OF IMMUNOLOGY, vol. 157, no. 7, 1 October 1996 (1996-10-01), pages 3039 - 3045, XP002170617 *
POGUE REBECCA R ET AL: "Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 92, no. 18, 1995, 1995, pages 8166 - 8170, XP002170616, ISSN: 0027-8424 *
TOURDOT S, OUKKA M, MANUGUERRA JC, MAGAFA V, VERGNON I, RICHE N, BRULEY-ROSSET M, CORDOPATIS P, KOSMATOPOULOS K: "Chimeric peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity: application in antiviral vaccination", JOURNAL OF IMMUNOLOGY, vol. 159, no. 5, 1 September 1997 (1997-09-01), pages 2391 - 2398, XP002170618 *

Also Published As

Publication number Publication date
US20040072240A1 (en) 2004-04-15
ES2296778T3 (es) 2008-05-01
EP1309860B1 (fr) 2007-11-14
CA2416761A1 (fr) 2002-01-31
AU2001278555A1 (en) 2002-02-05
EP1309860A2 (fr) 2003-05-14
US7425606B2 (en) 2008-09-16
WO2002008716A2 (fr) 2002-01-31
US7976843B2 (en) 2011-07-12
CA2416761C (fr) 2013-04-23
DE60131413T2 (de) 2008-09-04
FR2812087B1 (fr) 2007-05-11
PT1309860E (pt) 2008-02-25
ATE378590T1 (de) 2007-11-15
DE60131413D1 (de) 2007-12-27
DK1309860T3 (da) 2008-03-17
FR2812087A1 (fr) 2002-01-25
US20090269363A1 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
WO2006076410A3 (fr) Vaccins peptidiques hybrides a base d'epitope antigenique/li -key
ATE468127T1 (de) Ii-key/antigene epitop-hybrid-peptid-vakzine
AU3843797A (en) Gnrh-leukotoxin chimeras
EP1619202A3 (fr) procedes immunotherapeutiques utilisant des epitopes de wt-1 et gata-1
CA2248667A1 (fr) Peptides de fixation de hla-a2.1 et leurs utilisations
JP2003522200A5 (fr)
MX9706009A (es) Quimeras de gnrh-leucotoxina.
GB2348808A (en) Methods and compositions for desensitisation
PT1309860E (pt) Método para despistar péptidos para utilização em imunoterapia
WO2001083559A3 (fr) Variants de protéines à immunogénicité modifiée
KR970704461A (ko) Hla 결합 펩티드 및 그의 용도(hla binding peptides and their uses)
WO1999050424A3 (fr) Preparation et utilisation d'antigenes
DK1335742T3 (da) Anvendelse af peptider afledt af apoB100 til fremstilling af en vaccine/et diagnostisk middel mod atherosclerose
SE9402089D0 (sv) Recombinant allergen, fragments thereof, corresponding recombinant DNA molecules, vectors and hosts containing the DNA molecules, diagnostic and therapeutic uses of said allergens and fragments
JP2001516567A5 (fr)
CA2542104A1 (fr) Methode d'identification d'epitopes relies a l'immunogenicite de produits biopharmaceutiques
WO2001040281A3 (fr) Procede de réduction de l'immunogénécité de proteines heterologues par l'elimination d'epitopes de lymphocytes t
ATE408620T1 (de) Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16
DE50115391D1 (de) Rekombinante Allergene aus der Dörrobstmotte Plodia interpunctella
RU2001127439A (ru) Пептиды из последовательности Т-вируса и моноспецифические антитела, связывающиеся с ТТ-вирусом
PE20010239A1 (es) Gen derivado de lawsonia y polipeptidos, peptidos y proteinas de hemolisina relacionados y sus usos
PE20010316A1 (es) GEN DERIVADO DE LAWSONIA Y POLIPEPTIDOS, PEPTIDOS Y PROTEINAS FlgE RELACIONADOS Y SUS USOS
WO2001029224A3 (fr) Homologue zgpa1 de peptide de granulocyte
WO2004056316A3 (fr) Vaccins contre la proteine tat de vih servant a generer des anticorps neutralisants
EP0392820A3 (fr) Analogues de la protéine du plasmodium circumsporozoite sans séquences répétées

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2416761

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001956629

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001956629

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10333430

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2003133458

Country of ref document: RU

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2001956629

Country of ref document: EP